Our breadth of experience ranges from standard immunophenotyping to flow cytometry assays for elucidation of intracellular markers. We also have the ability to customize our antibody panels to meet our client’s specific needs. Please inquire to start the scientific discussion.Learn More
Flow cytometry can be a powerful tool for the evaluation of Receptor Occupancy (RO) to provide an assessment of the therapeutic binding to the target receptor. This can be evaluated using direct or indirect methods. Please inquire to start the scientific discussion.Learn More
We have full service cell culture capabilities to demonstrate whether or not a cell has the capacity of performing certain functions. Currently we have assays to evaluate Natural Killer Cell functional and a Basophil Activation Test (BAT). Please inquire to start the scientific discussion.Learn More
The separation of Peripheral Blood Mononuclear Cells (PBMC) may be required for certain applications in flow cytometry. At FCSL we can provide support for PBMC separation as required for your specific flow cytometry assay. Please inquire to start the scientific discussion.Learn More
Flow Contract Site Laboratory, LLC is a contract flow lab that provides state-of-the-art flow cytometry services to support all researchers, biotech and pharmaceutical companies in the process of drug development.
We provide full flow cytometry services (FACS services) from experimental design to specimen processing, acquisition, and data analysis for all stages of drug development from exploratory research, to preclinical GLP and finally in support of clinical trials.
We pride ourselves on the ability to customize any flow cytometry assays to meet our client’s needs. We have extensive experience in data collection and analysis utilizing both straight-forward and complex gating strategies.
Flow Contract Site Laboratory, LLC, as your contract flow lab, can rapidly set up and develop your flow cytometry project with accurate reporting in a cost effective and timely manner. We are ready to collaborate with your next stage of research and provide solutions to your flow cytometry development needs.
SCOTTSDALE, ARIZONA, USA, February 1, 2024 /EINPresswire.com/ — Translational Drug Development (TD2), a leading provider of comprehensive preclinical drug development, translational and clinical trial services, is pleased to announce its acquisition of Flow Contract Site Laboratory (FCSL) located in Bothell, Washington. This strategic move strengthens TD2’s oncology ecosystem, enhancing its capabilities in flow cytometry and cell-based assays.
The acquisition of FCSL reaffirms TD2’s commitment to delivering innovative solutions and expediting the development of cancer therapeutics. Flow cytometry is an important tool in drug discovery and development, enabling precise cellular analysis and characterization. With this acquisition, TD2 expands its capabilities and strengthens its leadership in immuno-oncology.
“We are thrilled to welcome the talented team and cutting-edge technology of FCSL to the TD2 family,” said Dr. Stephen Gately, President and CEO of TD2. “This strategic partnership aligns perfectly with our mission to improve drug development and offer extensive scientific expertise to our clients.”
The FCSL team are well-respected as scientific leaders in flow cytometry and the site is equipped with state-of-the-art instrumentation, including higher-dimensional spectral flow cytometers. The site is synergistic with TD2’s current preclinical services and enhances its capacity while expanding clinical capabilities, offering clients access to advanced technologies and expertise in flow cytometry and cell-based assays.
“Our team is very pleased to solidify our previous long-term working relationship with FCSL by completing this acquisition. For over 8 years, TD2 and FCSL have worked collaboratively to bring solutions to our clients, and we look forward to our combined efforts towards accelerating oncology therapeutics development,” said Paul Gonzales, Vice President Nonclinical Operations.
“We are excited to join forces with TD2, as this partnership marks an exciting chapter in the growth and expansion of our flow cytometry services,” said Lynette Brown, President of FCSL “By integrating with TD2, we will not only enhance our capabilities but also offer our clients access to a broader range of services. Together, we look forward to delivering even more comprehensive and innovative solutions to advance drug discovery and development.”
TD2 continues to be a trusted partner in the pharmaceutical and biotech industry, offering a wide range of services, including preclinical and clinical trial management, translational research, and regulatory strategy and support. With the addition of the FCSL, TD2 enhances its ability to streamline drug development processes and accelerate the path to market for innovative therapies.Read More